ChemicalBook > Product Catalog > Biochemical Engineering > Biochemical Reagents > Agonist Inhibitors > 1-(4-Fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-3-pyridinecarboxamide
1-(4-Fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-3-pyridinecarboxamide
1-(4-Fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-3-pyridinecarboxamide Basic information
- Product Name:
- 1-(4-Fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-3-pyridinecarboxamide
- Synonyms:
-
- 1-(4-Fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-3-pyridinecarboxamide
- BMS-2
- BMS-21-(4-Fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-3-pyridinecarboxamide
- N-(4-((1H-Pyrrolo[2,3-b]pyridin-4-yl)oxy)-3-fluorophenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydro
- N-(4-(1H-PYRROLO[2,3-B]PYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-1-(4-FLUOROPHENYL)-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE
- BMS2;BMS 2
- 3-Pyridinecarboxamide, 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-
- SYN-1022
- CAS:
- 888719-03-7
- MF:
- C25H16F2N4O3
- MW:
- 458.42
- Mol File:
- 888719-03-7.mol
More
Less
1-(4-Fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-3-pyridinecarboxamide Chemical Properties
- Melting point:
- 212-214℃
- Density
- 1.41
- storage temp.
- 2-8°C
- solubility
- ethanol: 1mg/mL
DMSO: 10mg/mL - form
- Solid
- pka
- 10.72±0.70(Predicted)
- color
- Off-white to light yellow
- InChI
- 1S/C25H16F2N4O3/c26-15-3-6-17(7-4-15)31-13-1-2-19(25(31)33)24(32)30-16-5-8-22(20(27)14-16)34-21-10-12-29-23-18(21)9-11-28-23/h1-14H,(H,28,29)(H,30,32)
- InChIKey
- OBSFXHDOLBYWRJ-UHFFFAOYSA-N
More
Less
1-(4-Fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-3-pyridinecarboxamide Usage And Synthesis
Uses
BMS-2 is a potent MET kinase inhibitor.
in vivo
MET kinase-IN-4 (Compound 2) (i.v., p.o.; 5, 10 mg/kg) possesses a favorable pharmacokinetic profile in mice[1].
MET kinase-IN-4 (p.o.; 6.25, 12.5, 25 and 50 mg/kg; once a day) demonstrates significant in vivo antitumor activity in the GTL-16 human gastric carcinoma xenograft model[1].
| Animal Model: | Mice[1] |
| Dosage: | 5, 10 mg/kg |
| Administration: | IV, PO |
| Result: | Showed extensive extravascular distribution and a favorable half-life. |
| Animal Model: | Nude mice[1] |
| Dosage: | 6.25, 12.5, 25 and 50 mg/kg |
| Administration: | PO, once a day |
| Result: | Showed antitumor activity in dose-dependet. |
1-(4-Fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-1,2-dihydro-2-oxo-3-pyridinecarboxamideSupplier
ZHIWE CHEMTECH CO LTD
- Tel
- 021-20221225 13917446399
- zwchem@163.com
Shanghai Topbiochem Technology Co., Ltd
- Tel
- 021-58170097
- info@topbiochem.com
SYN|thesis med chem P/L
- Tel
- +86-021-50720296
- service@synkinase.com
Pharmacodia (Beijing) Co.,Ltd
- Tel
- +86-400-851-9921
- sales@pharmacodia.com
Shanghai EFE Biological Technology Co., Ltd.
- Tel
- 021-65675885 18964387627
- info@efebio.com